Healthcare / BiotechnologyLSE
$140.80
+4.80 (+3.53%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-158.5M · quality 77.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.4B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-31.3%
↓Gross Margin
58.6%
↑Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.1%
FCF CAGR
—
FCF margin
-51.9%
FCF / Net income
0.80x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $223.9M · net income $-145.2M · FCF $-116.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $223.9M | $223.9M | $183.2M | $169.7M | $198.6M |
| Net Income | $-145.2M | $-145.2M | $-146.2M | $-154.5M | $-91.0M |
| EBITDA | $-87.3M | $-87.3M | $-93.1M | $-105.9M | $-49.9M |
| EPS | -0.15 | -0.15 | -0.16 | -0.19 | -0.11 |
| Gross Margin | 58.6% | 58.6% | 57.5% | 53.3% | 62.3% |
| Operating Margin | -69.4% | -69.4% | -83.1% | -99.4% | -49.6% |
| Net Margin | -64.9% | -64.9% | -79.8% | -91.1% | -45.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.09 | 0.09 | 0.08 | 0.06 | 0.05 |
| Current Ratio | 3.56 | 3.56 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-116.3M | $-116.3M | $-158.5M | $-164.6M | $-91.6M |
| Returns | |||||
| ROE | -31.3% | -31.3% | -24.9% | -24.0% | -13.1% |
| Valuation | |||||
| P/B | 292.05 | 292.05 | 200.60 | 252.58 | 308.21 |
| Growth & Yield | |||||
| Revenue Growth | 22.2% | 22.2% | 8.0% | -14.6% | — |
| EPS Growth | 7.3% | 7.3% | 14.3% | -72.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+16.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.16 → -0.15
Residual
+16.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.